Stocks · News reference

LB Pharmaceuticals shares are trading higher after the company announced accelerated timing for topline results from the Phase 3 NOVA-2 trial of LB-102 in Schizophrenia.

Jul 22, 2026, 5:55 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 24, 2026, 1:30 PMAvi Kapoor
Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.
Read original at benzinga
ADI ALKT ATRC BRCB CMG
BenzingaAug 24, 2026, 10:06 AMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60
Read original at benzinga
LBRX
BenzingaAug 12, 2026, 12:05 PMBenzinga Newsdesk
BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54
BMO Capital analyst Malcolm Hoffman maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform and raises the price target from $46 to $54.
Read original at benzinga
LBRX
SEC EDGARAug 11, 2026, 12:05 PMSEC EDGAR
8-K filing — LB PHARMACEUTICALS INC (LBRX)
Filed: 2026-08-11 AccNo: 0001193125-26-343479 Size: 211 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
LBRX